Aimee DeGaetano Joins Vastrax as Global Head of Commercial and Clinical Affairs

Leading Clinical Research Organization Strengthens Expertise in Neurovascular Field


ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs.

“Our dedication to accelerating advancements in the vascular sector is unwavering, and Aimee’s appointment reinforces this commitment,” said Ryan Bouchard, President and CEO of Vastrax. “Aimee’s expertise aligns seamlessly with our mission, and we are thrilled to have her lead our Global Commercial Strategy and Clinical Affairs. Aimee’s appointment comes at a crucial juncture in Vastrax’s journey as we continue to lead the way in neurovascular clinical trials. Her expertise will significantly contribute to our efforts in helping our clients advance ground-breaking technological solutions that have the potential to transform the lives of patients worldwide.”

Aimee is a registered dietician (RD) and holds a master’s in public health (clinical epidemiology). She is currently completing a doctorate in health science at Eastern Virginia Medical School. She has held various leadership roles in medical technology companies, focusing on clinical trials, medical affairs, and key opinion leader engagement. Her unique blend of skills perfectly aligns with Vastrax’s multifaceted approach to driving efficient technology approvals.

“I am honored to contribute to Vastrax’s pivotal role in assisting our clients to expedite the introduction of groundbreaking vascular technologies,” commented Aimee DeGaetano. “Together, we will fortify our commitment to clinical trials, integrating novel innovations, strategies and technologies to enhance patient care and improve outcomes.”

About Vastrax, Inc.

Vastrax is a cutting-edge full-service Contract Research Organization specializing in expediting the development of cutting-edge technologies in the vascular market. With an expert team possessing over 100 years of combined clinical, commercial, and regulatory experience, Vastrax is at the forefront of pioneering innovations, delivering transformative products to market efficiently. For more information please visit us at www.vastrax.com and follow us on LinkedIn.

Contacts

Tara DiMilia

908-369-7168

Tara.DiMilia@tmstrat.com

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

4 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

7 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

7 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

7 hours ago